書(shū)目名稱(chēng) | Ketamine for Treatment-Resistant Depression |
副標(biāo)題 | The First Decade of |
編輯 | Sanjay J. Mathew,Carlos A. Zarate, Jr. |
視頻video | http://file.papertrans.cn/543/542503/542503.mp4 |
概述 | First book to systematically review the robust clinical and preclinical research on ketamine use for treatment-resistant depression.Discusses the quest for rapid antidepressant, “ketamine-like” pharma |
圖書(shū)封面 |  |
描述 | .This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants..Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic moleculartargets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underl |
出版日期 | Book 2016 |
關(guān)鍵詞 | Alcohol and Substance Use; Anhedonia; Bipolar Disorder; Clinical Trials; Electroconvulsive Therapy; Gluta |
版次 | 1 |
doi | https://doi.org/10.1007/978-3-319-42925-0 |
isbn_softcover | 978-3-319-82695-0 |
isbn_ebook | 978-3-319-42925-0 |
copyright | The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl |